Benjamin F. Edwards & Company Inc. lowered its stake in shares of Allergan PLC. (NYSE:AGN) by 18.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 507 shares of the company’s stock after selling 115 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Allergan PLC. were worth $123,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Crestwood Advisors Group LLC acquired a new stake in Allergan PLC. during the first quarter worth $103,000. Enterprise Financial Services Corp raised its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC raised its stake in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the last quarter. JNBA Financial Advisors raised its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. Finally, Webster Bank N. A. raised its stake in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Shares of Allergan PLC. (NYSE AGN) opened at 222.97 on Tuesday. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market cap of $74.54 billion, a P/E ratio of 6.79 and a beta of 1.16. The company’s 50-day moving average price is $242.74 and its 200-day moving average price is $238.85.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.35 EPS. Equities analysts forecast that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.26%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/22/benjamin-f-edwards-company-inc-sells-115-shares-of-allergan-plc-agn.html.

A number of analysts have weighed in on AGN shares. Citigroup Inc. increased their target price on Allergan PLC. to $261.00 and gave the stock a “buy” rating in a research note on Monday, April 24th. Royal Bank Of Canada increased their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a research note on Wednesday, May 10th. UBS AG reiterated a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.